Global Nanopharmaceutical Drugs Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Nanopharmaceutical Drugs Market Research Report 2024
Nanopharmaceuticals are colloidal particles of 10 to 1,000 nanometers (1 micron) in size. They are widely used in drug delivery. Nanopharmaceuticals are diverse both in their shape and composition and often offer an advantage as compared to their “bulk” counterparts primarily because of size.
There are two types of nanopharmaceuticals(1) those where the therapeutic molecules are themselves the drug (i.e.,the therapeutic compound itself also functions as its own carrier); and (2) those where the therapeutic molecules are directly coupled (functionalized, entrapped, or coated) to a nanoparticle carrier.
According to Mr Accuracy reports’s new survey, global Nanopharmaceutical Drugs market is projected to reach US$ 54830 million in 2034, increasing from US$ 30960 million in 2024, with the CAGR of 8.3% during the period of 2023 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Nanopharmaceutical Drugs market research.
USA is the largest Nanopharmaceuticals market with about 59% market share. Europe is follower, accounting for about 33% market share.
The key players are Merck, Pfizer, Novartis, Abbott, GlaxoSmithKline, Roche, Sanofi, Eli Lilly, Astrazeneca, Johnson & Johnson, Celgene, Novavax, Stryker, Gilead Sciences, OSI Pharmaceuticals, Kadmon Pharmaceuticals, Samyang Biopharm, Mitsubishi Pharma, Kaken Pharmaceutical, Selecta Biosciences, Par Pharmaceutical, Cerulean Pharma, Navidea Biopharmaceuticals, Lummy etc. Top 3 companies occupied about 34% market share.
Report Scope
This report, based on historical analysis (2018-2024) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Nanopharmaceutical Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Pfizer
Merck
AstraZeneca
Gilead Sciences
Abbvie
Amgen
Roche
Novartis
Sanofi
Segment by Type
Liposomes
Polymer
Nanocrystals
Protein
Others
Oncology
Neurology
Immunology
Anti-Infective
Cardiovascular
Others
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The Nanopharmaceutical Drugs report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
There are two types of nanopharmaceuticals(1) those where the therapeutic molecules are themselves the drug (i.e.,the therapeutic compound itself also functions as its own carrier); and (2) those where the therapeutic molecules are directly coupled (functionalized, entrapped, or coated) to a nanoparticle carrier.
According to Mr Accuracy reports’s new survey, global Nanopharmaceutical Drugs market is projected to reach US$ 54830 million in 2034, increasing from US$ 30960 million in 2024, with the CAGR of 8.3% during the period of 2023 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Nanopharmaceutical Drugs market research.
USA is the largest Nanopharmaceuticals market with about 59% market share. Europe is follower, accounting for about 33% market share.
The key players are Merck, Pfizer, Novartis, Abbott, GlaxoSmithKline, Roche, Sanofi, Eli Lilly, Astrazeneca, Johnson & Johnson, Celgene, Novavax, Stryker, Gilead Sciences, OSI Pharmaceuticals, Kadmon Pharmaceuticals, Samyang Biopharm, Mitsubishi Pharma, Kaken Pharmaceutical, Selecta Biosciences, Par Pharmaceutical, Cerulean Pharma, Navidea Biopharmaceuticals, Lummy etc. Top 3 companies occupied about 34% market share.
Report Scope
This report, based on historical analysis (2018-2024) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Nanopharmaceutical Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Pfizer
Merck
AstraZeneca
Gilead Sciences
Abbvie
Amgen
Roche
Novartis
Sanofi
Segment by Type
Liposomes
Polymer
Nanocrystals
Protein
Others
Segment by Application
Oncology
Neurology
Immunology
Anti-Infective
Cardiovascular
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The Nanopharmaceutical Drugs report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices